Overview

Universal Anti-Viral Vaccine for Healthy Elderly Adults

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection against progression of the current outbreak of COVID-19 infection, and any future variants, strains, mutations of the causative SARS-CoV-2 virus as well as protection from any future currently unknown newly emergent novel viruses.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Immunovative Therapies, Ltd.
Collaborator:
Mirror Biologics, Inc.